Illinois Municipal Retirement Fund Invests $2.61 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Illinois Municipal Retirement Fund bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 107,858 shares of the company’s stock, valued at approximately $2,608,000.

Several other institutional investors also recently made changes to their positions in the stock. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the fourth quarter worth approximately $28,000. Raleigh Capital Management Inc. raised its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at $48,000. GAMMA Investing LLC boosted its stake in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares during the last quarter. Finally, Principal Securities Inc. grew its holdings in Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after acquiring an additional 1,002 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Bank of America lifted their price target on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research note on Thursday, February 20th. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Truist Financial lifted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $35.71.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 33,513 shares of Hims & Hers Health stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $1,118,296.76. This trade represents a 50.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock valued at $38,080,320 in the last three months. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $41.30 on Friday. The stock has a market cap of $9.02 billion, a price-to-earnings ratio of 93.85 and a beta of 1.35. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The stock’s 50 day moving average price is $36.19 and its 200 day moving average price is $26.46.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.